Monmouth Junction-based Tris Pharma, a biopharmaceutical company focused on attention deficit hyperactivity disorder, addiction and neurological disorders, on Monday announced the Franchesca Fowler has been named chief compliance officer and vice president, general counsel.
Fowler will oversee all legal matters within the company, including legal compliance, intellectual property management, litigation and more.
“I am pleased to welcome Franchesca to the executive team, and I am confident that she will be a tremendous asset to the organization as we continue to serve individuals with ADHD through our portfolio of marketed products and advance our robust pipeline of investigational therapies for the treatment of ADHD, pain, addiction and neurological disorders,” Ketan Mehta, founder and CEO at Tris Pharma, said.
“With her profound legal expertise and strategic vision, Franchesca has demonstrated an ability to navigate the complex legal landscape of the pharmaceutical industry and, together, we look forward to continuing to make a meaningful impact for patients who are not well-served by current treatment paradigms.”
Fowler brings 15 years of dynamic experience to Tris Pharma, most recently serving as the head of legal and compliance, as well as the global associate general counsel, for Demant, a global medical device company based in Copenhagen, Denmark. At Demant, she spearheaded legal and compliance efforts for the company’s subsidiaries in the U.S., spanning retail, manufacturing and diagnostics, as well as fostered a culture of compliance and authenticity within its internal organizations. Prior to Demant, Fowler supported the GE life science business as a legal deal support leader.
“I am passionate about inspiring teams to achieve their personal best and promote authenticity, psychological safety and accountability throughout the organization,” Fowler said. “My decision to join Tris Pharma was driven not only by its exciting pipeline and growth prospects, but also the exceptional team of dedicated professionals. The collaborative and forward-thinking nature of the people here aligns seamlessly with my values, and I am eager to work alongside them to achieve our shared goal of advancing groundbreaking initiatives in ADHD, pain, addiction and neurological disorders.”